drugset / Trial / NCT06693973
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Phase 0
Recruiting
13 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
SupermAb (BeiJing) Biotech Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether AcNK-Sup003 cell injection is safe and effective in the treatment of elapsed or refractory B-cell non-Hodgkin's lymphoma.
Timeline
- Start
- 2023-12-27
- Primary completion
- 2026-01-13
- Completion
- 2026-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AcNK-Sup003 | Cell therapy | 3e+08 cells | — |
| Subject | AcNK-Sup003 | Cell therapy | 1e+09 cells | — |
| Subject | AcNK-Sup003 | Cell therapy | 3e+09 cells | — |
| Subject | AcNK-Sup003 | Cell therapy | 9e+09 cells | — |